Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Reata gets another shot in Friedreich’s ataxia
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Upcoming events – Atara and Aslan await validating results
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Vizai hopes Medtronic deal will boost sales of its tech – and vice versa
Medtronic decides that Solitaire is best played with a partner.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Marinus leaves the way clear for Sage
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Nuplazid’s schizophrenia flop provides Advance warning
Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
Novartis needs new launches to keep up momentum
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.